版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Corticosteroid-InducedOsteoporosis2012第一页,共四十九页。编辑课件OsteoporosisSystemicskeletaldiseaseLowbonemassMicroarchitecturaldeteriorationofbonetissueIncreaseinbonefragilityandfracturesusceptibility第二页,共四十九页。编辑课件ClinicalBurdenofCIOMostcommonformofdrug-relatedosteoporosisinmenandwomenOccursatanyage,inbothgenders,acrossracesUpto50%ofpatientsonchronicsteroidtherapysustainosteoporoticfracturesand/ordeveloposteonecrosis第三页,共四十九页。编辑课件Corticosteroid-InducedOsteoporosisCommon,iatrogenicformofsecondaryosteoporosisAssociatedwithcorticosteroiduseinchronic,noninfectiousmedicalconditionsAsthma -NephroticsyndromeChroniclungdisease -TransplantationRheumatologicdisorders -etcInflammatoryboweldisease第四页,共四十九页。编辑课件Clinicalsignificant-Increasebonelossandfracture:6Mo.-Trabecular>corticalbone-7.5mgofprednisolone(equivalent)-Incidenceofosteoporosis~30-50%-Vertebralfracture30-35%,hipfracture50%-Rateofboneloss2-4%peryear-Alternatedayregimen,inhalesteroids第五页,共四十九页。编辑课件FractureRiskandDoseofCorticosteroidsRelativeriskoffracturebydosagesofcorticosteroidsofprednisolone.vanStaaTP,etal,1998.
01234562.5mg/d2.5-7.5mg/d>7.5mg/dRelativeriskoffracturecomparedwithcontrolHipfractureVertebralfracture第六页,共四十九页。编辑课件CIOinPatientsWithAsthmaRelationshipofpercentagepredictedbonedensitytodurationofcorticosteroidusein44corticosteroid-treatedasthmaticpatients.SchatzM,DudlJ,ZeigerRS,etal.AllergyProc.1993;14:341-345.Reprintedwithpermission.Percentpredictedbonedensityr=-0.39(P=0.009)Durationofcorticosteroiduse(years)12010080604024681012141618202224262830323436第七页,共四十九页。编辑课件CIOinPatientsWithRheumatoidArthritisCS=corticosteroid;therapy=7mgprednisoneequivalentperday.DensitychangemeasuredaschangeinabsoluteorZscore(differenceinstandarddeviationcomparedwithhealthyage-matchedcontrolsofthesameraceandsex)comparedtobaseline.VerhoevenAC,etal,1997.第八页,共四十九页。编辑课件*P<0.001;**P=0.002.PercentageofSLEpatients(N=97)withlowBMD,asmeasuredbyDXA.KipenY,etal,1997.CIOandSystemicLupusErythematosus******第九页,共四十九页。编辑课件PotentialFactorsCausingBoneLossinInflammatoryBowelDiseaseCorticosteroidsVitaminD/CalciumdeficiencyPoornutritionalstatusInflammationPhysicalinactivityConcurrentmedications(immunosuppressiveagents)第十页,共四十九页。编辑课件CIOandChronicObstructivePulmonaryDisease*P<0.05vs.ISUorNSU;**P<0.005vsISU.McEvoyCE,etal,1998.***第十一页,共四十九页。编辑课件PathophysiologyofCIO:OverviewBoneremodelingoccursthroughoutadulthoodOsteoporosisresultsfromanimbalancebetweenosteoclastandosteoblastactivityTwometabolicabnormalitiescontributetoincreasedboneresorptionSecondaryhyperparathyroidismduetodecreasedGIabsorptionandurinaryexcretionofcalciumAlteredgonadalfunctionanddecreasedadrenalproductionofandrogens第十二页,共四十九页。编辑课件PathophysiologyofCIO
CalciumhomeostasisGonadalhormoneInhibitboneformationIncreaseboneresorptionother第十三页,共四十九页。编辑课件Calciumhomeostasis
DecreasecalciumandphosphatefromGItracts unknownmechanismIncreaseurinarycalciumexcretion decreasecalciumreabsorptionatdistaltubulesStimulatiomPTHsecretion第十四页,共四十九页。编辑课件GonadalhormoneeffectsDecreasesexhormone:direct&indirectDecreaseLHfrompituitarygland: estrogenandtestosteroneDecreasesynthesisfromadrenalglandsDecreasesexhormonebindingglobulin第十五页,共四十九页。编辑课件BoneformationandboneresorptionOsteoblast -inh.Osteoblastproliferation -decreasematrixsynthesis -increaseapoptosis -decreaseproteinsynthesis(type1collagenandnoncollagenousprotein -decreaseosteocalcin,IGF1,IGFBP3,5,insulin-likegrowthfactors,transforminggrowthfactorB,prostaglandinE第十六页,共四十九页。编辑课件Osteoclast increaseosteoclastactivity increaseapoptosisofmatureosteoclastBoneformationandboneresorption第十七页,共四十九页。编辑课件OsteoblastproliferationApoptosis OBnumberProteinsynthesis BoneformationDifferentiation
BonemassFracture RiskAndrogenOsteoclastapoptosis BoneresorptionOsteoclastformation PTH Calciumandphosphateabsorption(gutandkidney)
Glucocorticoid第十八页,共四十九页。编辑课件DiagnosisofCIO:
InitialClinicalWork-UpMedicalhistoryRiskfactorsforbonelossPhysicalexamClinicalsignsandsymptoms第十九页,共四十九页。编辑课件PatientEvaluation
HistoryDocumentationofheight,weight,musclestrength, balance,vision
DocumentationofmedicalhistoryDocumentationofmenstrualhistory,infertilityinmenFracturehistoryandFamilyhistoryoffracturesOtherriskfactorsforosteoporosis:-Lifestylesinfluences:calciumandvitaminDintake, smoking,alcoholintake,medications,preventionoffalling-Patienteducation:preventionoffalling,exerciseGeneralhealthandprognosis第二十页,共四十九页。编辑课件PatientEvaluationPhysicalexaminationEvidenceofosteoporosis:evidenceoffracture,kyphosis,lossofheight,musclestrengthandsizeGeneralphysicalfindings:assessmentofunderlyingdisorder,othermedicalconditions第二十一页,共四十九页。编辑课件PatientEvaluationCompletebloodcountanderythrocyte sedimentationrate(ESR)Serumcalcium,phosphate,creatinine,electrolyte,alkalinephosphatase,25-hydroxyvitaminD,estradiol,testosterone(male)24hr-UrinarycalciumandcreatinineBMDofspineandhipX-raysofappropriateareaslaboratory第二十二页,共四十九页。编辑课件
DiagnosticCriteria* Classification T=0to-1SD Normal T=-1to-2.5SD Osteopenia T
-2.5SD Osteoporosis T
-2.5SD+fragilityfractures Severeosteoporosis*Measuredin“Tscores,”ie,thenumberofstandarddeviationsbeloworabovethepeakbonemassinayoungadultreferencepopulationofthesamesex;SD=standarddeviation.WHOCriteriaforAssessingDiseaseSeverity第二十三页,共四十九页。编辑课件GuidelinesforBMDMeasurementBaselineBMDpriorto/within6monthsofinitiatingtherapyAntero-posteriormeasurementoflumbarspineandfemoralneckFollow-upat6and12months,annuallythereafteruntilbonemassstabilizesMeasuringhipalonemaymissmorerapidlossinspine第二十四页,共四十九页。编辑课件ManagementofCIO:GoalsofTreatmentReducefractureriskMaintaincurrentBMD,preventadditionalbonelossAlleviatepainassociatedwithexistingfracture(s)Maintain/increasemusclestrengthInitiatelifestylechangesasneeded第二十五页,共四十九页。编辑课件BMD,VitaminD,andCalciumAdachiJD,etal,1996.-12-10-8-6-4-206months12months18months24months30months36monthsChangeinlumbarspineBMD
frombaseline(%)VitaminD&calcium
Placebo第二十六页,共四十九页。编辑课件TreatmentHormonalreplacementtherapyCalcitoninBisphosphonatesActionInhibitboneresorptionPreventapoptosisofosteoblastsPartiallyreversebonelossPreventearlyresorptivephaseofbonelossInhibitboneresorptionMaintainorincreasebonemassPharmacologicTreatmentofCIO:Overview第二十七页,共四十九页。编辑课件PharmacologictreatmentofCIOThiazidediuretics increasecalciumabsorptionfromGItract decreaseurinarycalciumexcretionFluorides stimulateosteoblastactivityAnabolicsteroids increaseboneformation第二十八页,共四十九页。编辑课件PatientgroupPostmenopausalwomenPremenopausalwomenw/intact ovarianfunctions(ages13-50)MenRecommendationEstrogen+progestinforwomenwithintactuteriBisphosphonateorcalcitoninifHRTcontraindicated
Estrogen-containingOCs(50gestradiol)orequivalentBisphosphonateorcalcitoninif
estrogencontraindicatedTestosterone(ifserumtestosteronelevelslow)BisphosphonateorcalcitoniniftestosteronecontraindicatedHormoneReplacementTherapyintheTreatmentofCIO:ACRGuidelinesAmericanCollegeofRheumatologyTaskForceonOsteoporosisGuidelines,1996.第二十九页,共四十九页。编辑课件-0.06-0.04-0.0200.020.040.06Group1PrednisoneonlyGroup2Prednisone+ERTGroup3Control
Group4ERTonlyChangesinlumbarspineBMD(g/cm2)at1yearEstrogenReplacementTherapy
intheTreatmentofCIO*P=0.008vs.baseline;P=0.027betweengroups1and2.LukertBP,etal,1992.*第三十页,共四十九页。编辑课件TestosteroneReplacementTherapy
intheTreatmentofCIO*P=0.005vscontrol;P=0.05between-groupdifference.ReidIR,etal,1996.*-5.0-2.50.02.55.0TestosteronetherapyperiodControlperiodChangesinlumbarspineBMD(%)at1year第三十一页,共四十九页。编辑课件CyclicalEtidronateandPreventionofCorticosteroid-InducedBoneLoss*P<0.05between-groupdifference.AdachiJD,etal,1997.RouxC,etal,1998.**-4-3-2-1012LumbarspineFemoralneckTrochanterLumbarspineFemoralneckTrochanterChangesinBMDfrombaseline(%)at1yearEtidronateControl第三十二页,共四十九页。编辑课件0246Lumbarspine*FemoralneckTrochanterChangeinBMDfrombaseline(%)MenPre-menopausalwomenPost-menopausalwomenEtidronate:PooledResultsfrom
ThreeRandomizedTrials*P<0.05between-groupdifference.RouxC,etal,1998.第三十三页,共四十九页。编辑课件EfficacyofPamidronateinthe
PreventionofBoneLossBoutsenY,etal,1997.-6-4-202466months12months6months12monthsChangesinBMDfrombaseline(%)Pamidronate+calciumCalciumonly第三十四页,共四十九页。编辑课件EfficacyofAlendronateinIncreasingBMD*P<0.001vs.control;**P<0.01vs.control;†P<0.001vs.baseline,‡P<0.01vs.baseline;SaagKG,etal,1998.-1.5-0.50.51.52.53.5LumbarspineFemoralneckTrochanterTotalbodyChangeinBMDfrombaseline(%)at48weeksControlAlendronate5mgAlendronate10mg*********第三十五页,共四十九页。编辑课件EfficacyofAlendronate:TwoYearsFollow-Up*P<0.001vs.control;**P<0.01vs.control;†P<0.05vs.control.SaagKG,etal,1998.******††-4-3-2-101234LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)ControlAlendronate10mgAlendronate5mgAlendronate2.5mgyear1,10mgyear2第三十六页,共四十九页。编辑课件EffectofRisedronateonBMDinPatientsInitiatingCorticosteroidTherapy*P<0.05vscontrol.CohenS,etal,1998.******-4.0-2.00.02.04.0LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)at12monthsControlRisedronate2.5mgRisedronate5mg第三十七页,共四十九页。编辑课件EffectofRisedronateonBMDinPatientsonLong-TermCorticosteroidTherapy*P<0.05vs.control.DevogelaerJP,etal,1998.****-3.0-2.0-1.00.01.02.03.0LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)at12monthsControlRisedronate2.5mgRisedronate5mg第三十八页,共四十九页。编辑课件05101520PooledcontrolpatientsPooledrisedronatepatientsPatientswithvertebralfractures(%)EffectofRisedronateonVertebralFractureRatesPooledvertebralfractureratesfrom518patientsonsteroidtherapy.*P=0.016vs.control.ReidD,etal,1998.*第三十九页,共四十九页。编辑课件
Treatment Numberof Changeinlumbar
pooledtrials spineBMD(%)*
VitaminD 18 +1.96Calcitonin 11 +2.11 Bisphosphonates 18 +5.31†BisphosphonatesintheManagementofCIO:AMeta-Analysis*Comparedwithnotreatmentorwithcalciumalone†P=0.0001comparedwithcalcitoninorvitaminD第四十页,共四十九页。编辑课件Glucocorticoidtherapyevaluation
Plan-atstartofglucocorticoidtherapy 1.Minimizeglucocorticoiddose
2.Usealternatedaytherapy,topicalsteroidor bonesparingsteroidifpossible
3.Prescribeexercise(weightbaring),physicaltherapy, preventfalling4.Avoidsmokingandexcessalcohol5.Assureadequatecalciumintake6.Addsupplementcalciumupto1000-15000mgcalcium/day7.Addmultivitamincontaining400-800IUvitaminD8.BMDmeasurementofthespineandhip:ifT-scorelower than–1SDstartHRTandifmorethan–1SDstartHRT onlyinpostmenopausalwoman第四十一页,共四十九页。编辑课件GlucocorticoidtherapyevaluationReassessmentat2-3mo1.Reviewglucocorticoidtherapy:attempttodecreaseordiscontinue2.Assessexerciseandcalciumintake3.Measureserumcalcium,24hrurinarycalciumifmorethan4mg/kg/dusehydrochlorothiazide25-50mgtwicedaily
Reassessmentat6mo
1.Reviewglucocorticoidtherapyandminimize2.Assessexerciseandcalciumintake3.Repeatserumcalciumand24hrurinarycalciummeasurement4.Altercalcium/vitaminD/thiazidetherapyifnecessary5.Ifpateintistocontinueglucocorticoid,considertorepeatBMD6.ConsiderHRT/bisphosphonate/calcitonin第四十二页,共四十九页。编辑课件Glucocorticoidtherapyevaluation
Reassessmentat1yr
1.Reviewglucocorticoidtherapyandminimize2.Assessexerciseandcalciumintake3.Repeatserumcalciumand24hrurinarycalciummeasurement4.BMDmeasurement(spineandhip)5.Altercalcium/vitaminD/thiazidetherapyifnecessary6.Alterfurtherthereapyifbonelossifcontinues
Reassessmentthereafterifglucocorticoidscontinue1.Repeatannualassessmentasabove2.Changetherapyasneeded3.Considernewerdrugsastheybecomeavailable第四十三页,共四十九页。编辑课件ACRTaskForceonOsteoporosis:
InitiatingLong-TermCorticosteroidTherapyInitialhistory&physical,lab/DXAmeasurementsCalcium/vitaminDsupplementationPatienteducationTscore<-1InitiateHRT;bisphosphonatesorcalcitoninifHRTcontraindicatedTscore>-1MonitorregularlyOnemonthfollow-up:Obtain24hurinetomeasurecalciumIf>300mg/d:addthiazidediureticAdjustdosageofcalciumandvitaminDsupplementation6-12monthsfollow-up:RepeatBMDDecrease>5%:change/addmedicationIncrease,nochange,ordecrease<5%:nochangeintherapyAmericanCollegeofRheumatologyTaskForceonOsteoporosisGuidelines,1996.第四十四页,共四十九页。编辑课件
Anticipatedtherapywithglucocorticoid
Atraumaticfractures
Yes No
Calcium1500mg/dayyesMeasurementofbonemineraldensityVitaminD400-800IU/day Lowerthan2SDbelowthemeanforExercise>5%youngadultsorLowerthan1SDbelowtheScreenforhypogonadismbonelossmeanforaged-matchcontrols NoIfhypogonadismpresent:
Calcium1000mg/dayAddhormonereplacementwith VitaminD400-800IU/dayEstrogeninwomanandtestosteroneinmenExerciseCheckBMDinoneyear:addanti-resorpt
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 小学二年级道德与法治《小水滴的诉说》情境化活动教学设计
- 初中地理八年级交通运输业二阶三阶提升教学设计
- 初中九年级数学教学设计:相似三角形性质定理一的深度探究与创新应用
- 初中科学七年级下册项目化学习自制酸奶教学设计
- 初中七年级道德与法治“法治与改革相互促进”教学设计
- 初中生物学中考专题复习教学设计:生命的起源与生物进化脉络梳理
- 初中数学九年级沪教版第30章投影与视图考点易错教学设计
- 小学六年级综合实践活动《身边的能源》教学设计
- 八年级数学下册平均数中位数众数课堂训练教学设计
- 初中九年级语文中考命题作文十二题精准预测教学设计
- 2025上海虹桥镇村公司招聘笔试历年参考题库附带答案详解
- 圣诞超市促销活动策划方案
- 入团日常培养考察谈话记录范文
- 厂务运维管理办法
- 电信转正考试题库及答案
- T/CHES 105-2023 T/CHAS 090-2023医院节水管理规范
- 2024年秋新沪教牛津版英语三年级上册课件 Unit 6 第1课时
- 早产儿低体重儿护理课件
- JB-T 7072-2023 水轮机调速器及油压装置 系列型谱
- JBT 14645-2023 低温装置用密封垫片 (正式版)
- (高清版)JTGT 3650-01-2022 公路桥梁施工监控技术规程
评论
0/150
提交评论